Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method of nilotinib intermediate

A technology of methyl and trifluoromethyl, which is applied in the field of preparation of nilotinib intermediate 3--5-aniline, can solve the problems of low compound utilization rate, low compound yield, chromatographic purification not suitable for industrial operation, etc. , to achieve the effect of improving the utilization rate of raw materials

Active Publication Date: 2016-10-05
ESTEVE HUAYI PHARMA
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the applicant has found through experiments that during the two-step reaction process of preparing compound (I) from compound (VII), the utilization rate of compound (VII) is low, resulting in low yield of compound (I); and chromatographic purification is not suitable for industrialization operate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0026] The preparation method of the compound (I) provided by the present invention comprises: further reacting and converting the by-product compound (III) formed by the Curtis rearrangement of the compound (VII) into the compound (I).

[0027] The present invention has no special requirements on the source of the main raw material compound (VII), which can be commercially available or prepared according to the prior art.

[0028] In the preparation method of the compound (I) provided by the invention, the compound (III) as a reaction by-product can be isolated separately, and converted into the target compound (I) through further reaction; the compound (III) can also be separated without isolation, And together with compound (II) under the same reaction conditions, it can be converted into compound (I) at the same time.

[0029] But preferably compound (III) and compound (II) are not separated, but are converted into compound (I) simultaneously under the same reaction condit...

Embodiment 1

[0053] Compound (VII) (10 g), tert-butanol (300 mL), triethylamine (7.9 g) and diphenylphosphoryl azide (11.2 g) were added to a 500 mL reaction flask. Stirring was started, the mixture was heated to reflux and maintained at reflux for 16 hours, then cooled to room temperature, the solvent was removed by evaporation under reduced pressure, the residue was treated with water (150 mL) and extracted with ethyl acetate (2 x 150 mL). The extracts were combined, washed with brine (150 mL), dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give the crude product (12.1 g).

Embodiment 2

[0055] The crude product (12.1 g) obtained in Example 1 was purified by chromatography (silica gel, eluting with ethyl acetate containing 2% ethanol) to obtain two components, which were recrystallized from ether-hexane respectively to obtain a solid compound ( II) (5.25g) and solid compound (III) (3.76g).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a preparation method of a nilotinib intermediate, namely, 3-(trifluoromethyl)-5-(4-methyl-1H-imidazole-1-yl)aniline (I). The preparation method comprises the steps that 3-(trifluoromethyl)-5-(4-methyl-1H-imidazole-1-yl)benzoic acid (VII) is subjected to Curtius rearrangement to generate a by-product compound (III) and then subjected to further reacting to be converted into 3-(trifluoromethyl)-5-(4-methyl-1H-imidazole-1-yl)aniline (I). The preparation method has the advantages of being high in utilization rate of the raw materials and suitable for industrialized operation. Please see the formula in the description.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical intermediates, in particular to the nilotinib intermediate 3-(trifluoromethyl)-5-(4-methyl-1 H - a process for the preparation of imidazol-1-yl)aniline. Background technique [0002] Nilotinib, the chemical name is 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylphenyl]-3-[[ 4-(3-pyridyl)-2-pyrimidinyl]amino]benzamide is a highly selective oral tyrosine kinase inhibitor developed by Swiss Novartis Pharmaceuticals, and its monohydrochloride monohydrate was released in 2007 In October, it was approved by the US FDA for marketing, and it is clinically used for the treatment of chronic myelogenous leukemia that is ineffective for imatinib mesylate. Nilotinib can selectively inhibit Philadelphia chromosome-positive chronic myelogenous leukemia caused by mutations in tyrosinase and its coding gene through targeting. It has good tolerance, strong selectivity and significant curative e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D233/61
Inventor 赵立强王昭江宏董金徐晓飞郑国荣
Owner ESTEVE HUAYI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com